Using engineered immune cells to treat type 1 diabetes
Engineered Immune Cells for T1D
This study is looking at a new way to help people with type 1 diabetes by using specially modified immune cells that can better protect the insulin-producing cells in the body, which could lead to a more effective treatment for managing the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11058403 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for type 1 diabetes (T1D) by genetically engineering immune T regulatory cells (Treg) to enhance their ability to protect insulin-producing islet cells. The approach involves integrating chimeric antigen receptor (CAR) proteins into Treg cells, which may improve their targeting and activation against the immune response that destroys these cells. By evaluating how these engineered Treg cells can better interact with human islets and monocytes, the research aims to create a more effective immunotherapy for T1D. Patients may benefit from a potential new treatment that could preserve islet function and prevent further autoimmune damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with type 1 diabetes.
Not a fit: Patients with type 2 diabetes or other forms of diabetes unrelated to autoimmune mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that preserves insulin production in patients with type 1 diabetes.
How similar studies have performed: Previous research has shown promising results with CAR Treg therapies in cancer treatment, suggesting potential for success in autoimmune conditions like T1D.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Meyer, Everett — Stanford University
- Study coordinator: Meyer, Everett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.